BigHat Biosciences

BigHat’s Chief Business Officer, Elizabeth Schwarzbach, joined Judy Khan Shaw on NYSE Floor Talk to discuss BigHat’s mission and cutting-edge approach to drug discovery, which combines AI and ML with a rapid and high-quality laboratory to develop next-gen antibodies on our Milliner™ platform. Watch the full recording: https://lnkd.in/gG2CqdB3   

Please donate and support Peyton Greenside, BigHat's co-founder, as she hikes Kilimanjaro to help those suffering from Sickle Cell Disease.

🏔️Join us in supporting Peyton Greenside from the BigHat team as she takes on the Timmerman Traverse for Sickle Forward! 🌍✨ This September, Peyton will hike to the summit of Mt. Kilimanjaro (19,340 ft / 5,895 m) to raise funds for Sickle Cell Disease (SCD) diagnosis and treatment in sub-Saharan Africa. 💪🏔️ SCD affects millions, with the highest prevalence in sub-Saharan Africa. Many children go undiagnosed and lack access to basic treatment, leading to high mortality rates. We invite you to support Peyton and the entire Timmerman Traverse team in their cause to help fund systematic newborn screening and treatment programs in sub-Saharan Africa, saving countless lives and giving children the chance for a healthier future. To address the unmet need of patients with SCD, BigHat has designed a next-generation antibody now in preclinical development to treat and prevent SCD vaso-occlusive crises. Stay tuned for more information about our program! 📅 Expedition Dates: Sept. 11-17, 2024 🎯 Fundraising Goal: $50,000 🔗 Contributing to a collective $1 million effort Every dollar raised will be matched, doubling our impact! 💖 Your support can help save lives! Let's climb higher together! 🙌 https://lnkd.in/g6PyYPJt #TimmermanTraverse #SickleForward #BigHat #SCD #MtKilimanjaro

We welcome Tiffany Barth, Eman K. and Megan M.! Tiffany joins us as a Senior Software Engineer I on the Lab Systems engineering team. She will be focusing on projects aimed at deepening our integration with the lab and our proprietary LIMS, Reccy. Tiffany is a full-stack software engineer with over 14 years of experience working in biotech. Previously, she was a software engineer at Invitae working on building and maintaining tools for translating scientific literature into organized medical content. She graduated from Carnegie Mellon University with a double major in chemical engineering and biomedical engineering. Eman and Meg join us as Research Associates II to the Production team. They will help scale our production capabilities to meet the demand from our growing pipeline of programs. Eman earned her bachelor's degree in Natural Sciences from Minerva University in 2020. After three years of working at Color's high-throughput COVID-19 lab, she returned to academia and is now one year into pursuing a master's degree in biotechnology at the University of San Francisco Meg is a research associate with experience in lab operations and LC-MS based biomarker discovery. She graduated with a B.S. in Biology from Arizona State University in 2021 and subsequently transitioned to the Bay Area to pursue a career in biotech. Prior to joining BigHat, Meg served as a member of the proteomics R&D team at PrognomiQ Inc, where she actively participated in multiple cohort studies and platform development initiatives aimed at creating diagnostic assays for early detection of cancers and other complex diseases. Welcome to the BigHat team, Tiffany, Eman and Meg! https://lnkd.in/grt3Vjx9

We welcome Monique Merchant, Somnath Nirakari, and Josh Dillen! Monique joins us as a Scientist I as part of the Platform Biology team at BigHat. Monique will lead high-throughput Discovery cell-based productionization, spearheading cell line onboarding, cell-based assay validation, and characterization workflows for all discovery efforts. Monique is a biochemist with a hyper-fixation on neglected tropical diseases and the impacts of climate change on global health. Prior to joining BigHat, Monique worked between the United Kingdom and Brazil developing tools to combat Oropouche fever, creating preliminary diagnostic tests, vaccine candidates, and antibody therapies for Oropouche virus infections. Monique maintains expertise in the molecular biology of viral spike proteins and virus evolution with a Ph.D. in Medicine from the University of Cambridge, a M.S. from Yale University, and B.S. from Russell Sage College. Somnath joins us as Principal Engineer, Data Ops as part of our engineering team. He will work on improvements to our data infrastructure and dashboards. Somnath is an experienced software engineer with about 15 years of experience. His area of expertise is backend engineering, but having worked at multiple startups and wearing multiple hats, he has developed considerable skills in other software disciplines such as frontend development, DevOps, and platform engineering. When not working on features of a product, he is always looking at ways to make the product more reliable, faster, and fault-tolerant. He has a master's degree in computer science from the University of Florida. Before joining BigHat, Somnath worked in multiple startups in different domains such as healthcare, fintech, and consumer products. Josh joins us as an Associate Scientist in Biomolecular Characterization. He will assist in expanding our label-free biosensing capabilities, onboard characterization assays for our early-stage programs, and characterizing our late-stage lead candidates. Josh brings broad experience in protein science and expertise in biophysical characterization of large molecules. Prior to joining BigHat, Josh has contributed to a diverse range of drug development and discovery programs at Denali Therapeutics and Vir Biotechnology, Inc.. He earned his B.S. from the University of California, Santa Cruz and performed research in the DuBois lab to understand the neutralization of RSV by human antibodies. Welcome to the BigHat team, Monique, Somnath, and Josh! www.bighatbio.com/about  

Elizabeth Schwarzbach, CBO of BigHat, will join Ariel Katz (CEO & Co-Founder, H1) and Ginger Liau (Partner, Bio Fund, Andreessen Horowitz) for a panel discussion: “How AI is Transforming Pharmaceutical R&D” moderated by David Apfel (Head, External Innovation, R&D Data Science and Digital Health, Innovative Medicine, Johnson & Johnson) at the “How AI is Transforming Pharmaceutical R&D: from Discovery to Development” event hosted by Johnson & Johnson on June 13, 2024 4:45 pm EST. https://lnkd.in/gRz_9rBp 

Mark DePristo, CEO and co-founder of BigHat, will give his invited talk at this year’s BIO International Convention in San Diego, which will be held at the San Diego Convention Center on Wednesday, June 5, from 11:00 a.m. to 12:00 p.m. PT. In this talk, Mark will elaborate on how BigHat’s platform, Milliner™, leverages cutting-edge AI and machine learning technologies combined with advanced synthetic biology methods to design safer, more effective antibody therapies for patients suffering from today’s most intractable diseases. https://lnkd.in/gqX6qY9B

We welcome Noelle, Mimi and Kevin to BigHat! Kevin Lei, PhD joins us as Associate Director of Business Development. He will spearhead our efforts with prospective partners, external relations, competitive intelligence, and opportunity assessments of NTCs. Kevin brings a diverse set of experience in biopharma and techbio business development, as well as tech transfer in early-stage companies. Prior to joining BigHat, he focused on business development transactions in oncology in-licensing at Exelixis. Kevin has also worked on sell-side business development at multiple AI-driven drug discovery companies. He earned his PhD in Immunology from the University of Chicago and holds a B.A. in Molecule and Cell Biology from the University of California, Berkeley. Noelle Huskey Mullin joins us as Principal Scientist, Translational Research. Noelle will provide scientific and strategic leadership for our new internal therapeutic programs. She joins BigHat from Pfizer's Center for Therapeutic Innovation where she collaborated with academic partners to lead drug discovery programs in oncology and inflammatory disease. Prior to Pfizer she was a scientific co-founder at Prellis Biologics. Noelle received a PhD from the University of California, San Francisco and completed a postdoc at Stanford University, with a focus on oncogenic signaling pathways and tumor resistance mechanisms. Mimi Shilling joins us as Chief of Staff. Mimi will work directly with our CEO, CSO, and leadership team to enhance our growth, scale, and operational efficiency. She is an accomplished entrepreneur and operator and has held several strategic roles across a number of industries, including biotech, tech, consumer goods and finance. Prior to joining BigHat, Mimi was a Senior Director and head of operations at TenSixteen Bio, an early stage CHIP company, a strategic and commercial operations advisor to Excellos, a newly launched cell therapy CDMO, and a Senior Director of People and Places at Expanse, acquired by Palo Alto Networks, a cybersecurity start-up. She also co-founded and served as CEO of Powder, a novel consumer Bay Area retail company, which she successfully exited in 2019. Mimi received her MBA from Harvard Business School and a B.A. in Economics from Harvard University. Welcome to the BigHat team, Kevin, Noelle, and Mimi! https://lnkd.in/grt3Vjx9

Peyton Greenside, CSO and co-founder of BigHat, will give her invited talk, “Combining Active Learning with a Rapid Synthetic Biology Platform to Design Therapeutic Antibodies” at the 20th annual Protein and Antibody Engineering Summit (PEGS), in Boston, MA on Monday, May 13, 2024 11:00 AM EST. In this talk, Peyton will explain how BigHat leverages cutting-edge AI and machine learning technologies combined with advanced synthetic biology methods to design safer, more effective antibody therapies for patients suffering from today’s most intractable diseases. In addition, Peyton will also participate in the Panel Discussion: AI/ML in Antibody Discovery and Engineering: Reality, Hope, Future, and Hype alongside Andrew Bradbury (Specifica, a Q² Solutions Company), Andrew Waight (Merck), Paolo Marcatili (Novo Nordisk), and Joshua Meier (Absci) on Wednesday, 8:30 AM EST. https://lnkd.in/g6dpztsw #pegsummit

BigHat's CBO, Elizabeth Schwarzbach, will join the panel "Startup Mentality Meets Corporate Practice" at the Rahway Open House hosted by Merck Digital Sciences Studio, alongside Martin Akerman (Envisagenics), Rayees R. (Harmonic Discovery) and Ahmed Elnaiem (Kaleidoscope.bio) today, at 2 PM EST. To register and join the discussion: https://lu.ma/mdss-oh2024r